Bavarian will market Covid-19 vaccine on its own – but doesn't rule out future partners

In the past, the biotech firm has very publicly stated that partnerships are the way forward regarding its RSV candidate – but when it comes to the firm’s Covid-19 efforts, cards have been kept closer to the chest.

Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR

There’s no shortage of competition on the Covid-19 vaccine market, and things aren’t made easier for Danish biotech firm Bavarian Nordic by competitors being some of the biggest players in the world – remaining so even after a year and some time since the first vaccines against Covid-19 hit the market.

Last week, Bavarian Nordic publicized phase II data on its candidate, ABNCoV2, reporting generally positive news. Should everything go according to plan, the firm should have an approved vaccine, backed by the Danish government, ready for the market in 2023.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs